Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given a consensus recommendation of “Buy” by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $62.50.

A number of equities research analysts recently weighed in on the company. UBS Group assumed coverage on Jasper Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $38.00 price target for the company. Royal Bank of Canada decreased their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th. JMP Securities reissued a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a report on Monday, January 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, March 11th.

Jasper Therapeutics Trading Up 0.7 %

NASDAQ:JSPR opened at $4.23 on Friday. The stock has a market cap of $63.54 million, a price-to-earnings ratio of -0.89 and a beta of 2.55. The stock has a 50-day moving average price of $5.08 and a two-hundred day moving average price of $13.09. Jasper Therapeutics has a 1 year low of $3.13 and a 1 year high of $26.84.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.35). Sell-side analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several institutional investors have recently made changes to their positions in JSPR. Boxer Capital Management LLC purchased a new position in shares of Jasper Therapeutics during the fourth quarter worth about $7,483,000. Integral Health Asset Management LLC lifted its stake in Jasper Therapeutics by 85.7% in the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $13,897,000 after purchasing an additional 300,000 shares during the last quarter. Braidwell LP boosted its position in Jasper Therapeutics by 47.9% during the fourth quarter. Braidwell LP now owns 714,658 shares of the company’s stock valued at $15,279,000 after buying an additional 231,358 shares during the period. Soleus Capital Management L.P. lifted its position in Jasper Therapeutics by 11.2% in the fourth quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company’s stock valued at $31,951,000 after purchasing an additional 150,755 shares during the last quarter. Finally, Stempoint Capital LP purchased a new stake in Jasper Therapeutics during the 4th quarter valued at $2,892,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.